EcoDrugPlus

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSECRG00000016297
Gene Symbol: HMGCR
3 Cross references
272 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSECRG00000012435
Gene Symbol: PDPK1
3 Cross references
246 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSECRG00000022098
Gene Symbol: HPD
3 Cross references
207 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSECRG00000000817
Gene Symbol: NT5E
3 Cross references
251 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSECRG00000008968
Gene Symbol: HTR1A
3 Cross references
149 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSECRG00000000865
Gene Symbol: HTR1B
1 Cross references
244 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSECRG00000000658
Gene Symbol: HTR1E
3 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSECRG00000002946
Gene Symbol: HTR1F
3 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSECRG00000010648
Gene Symbol: LOC114662234
3 Cross references
228 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSECRG00000017005
Gene Symbol: HTR3A
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSECRG00000016924
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSECRG00000009860
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).